a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today
new data from Genzyme's clinical development programs for AUBAGIO®
(teriflunomide) and LEMTRADATM (alemtuzumab) will be
presented at the 28th Congress of the European Committee for
Treatment and Research in Multiple Sclerosis (ECTRIMS) in Lyon, France,
"The data to be presented at ECTRIMS are a reflection not only of the
comprehensive clinical development programs supporting AUBAGIO and
LEMTRADA, but of the unique commitment and substantial progress Genzyme
has made to date in bringing forward differentiated therapies in
multiple sclerosis," said Genzyme CEO and President, David Meeker.
Once-daily, oral AUBAGIO is now commercially available in the U.S.
following FDA approval in patients with relapsing forms of MS. Marketing
applications for AUBAGIO and LEMTRADA are currently under review by the
EMA and other regulatory authorities.
Key data from across the company's clinical development programs to be
presented are as follows. Abstracts are available on the ECTRIMS website.
TOWER (Teriflunomide Oral in people With
relapsing multiplE scleRosis)
TOWER is a randomized Phase III trial assessing once-daily oral AUBAGIO
(teriflunomide) in patients with relapsing multiple sclerosis. It is the
second Phase III study for AUBAGIO.
The efficacy and safety of teriflunomide in patients with relapsing
MS: results from TOWER, a phase III, placebo-controlled study
(Parallel Session 12 - 153; October 12; 3:10 p.m. CEST, 9:10 a.m. EDT).
CARE-MS II (Comparison of Alemtuzumab and Rebif
Efficacy in Multiple Sclerosis II)
CARE-MS II was a randomized Phase III clinical trial designed to
evaluate whether the investigational MS therapy LEMTRADA (alemtuzumab)
could achieve meaningful efficacy and safety improvements over the
approved, active comparator Rebif (subcutaneous interferon beta-1a 44
Efficacy of alemtuzumab in relapsing-remitting multiple sclerosis
patients who relapsed on prior therapy: subgroup analyses by previous
DMT use (Poster Session 1 - P483; October 11; 3:30 p.m. CEST, 9:30
Disability improvement with alemtuzumab vs. interferon beta-1a in
relapsing-remitting multiple sclerosis patients who relapsed on prior
therapy (Poster Session 2 - P922; October 12; 3:30 p.m. CEST, 9:30
Effect of alemtuzumab vs. Rebif® on brain MRI measurements: Results of
CARE-MS II (Poster Session 2 - P877; October 12; 3:30 p.m. CEST, 9:30
Safety of alemtuzumab in relapsing-remitting multiple sclerosis
patients who relapsed on prior therapy (Poster Session 1 - P545;
October 11; 3:30 p.m. CEST, 9:30 a.m. EDT).
Additional Genzyme MS portfolio data, in addition to the Genzyme
satellite symposia to be featured at ECTRIMS include: